ASCO 2021 – Donald Harvey
Donald Harvey discusses lung cancer from the point of view of clinical pharmacology, targets in the area of antibody-drug conjugates, the role of proteolysis targeting chimeras (PROTACs) in the treatment landscape, highlights mechanisms of resistance to small molecule inhibitors and draws attention to clinical trial design to better meet the demands of modern drug development.
Here is the full ASCO 2021 report.
More posts
Opening up new vistas for patients with SCLC
Opening up new vistas for patients with SCLC Cisplatin vs. carboplatin in LS-SCL
Enhancing immunosupportive mechanisms via anti-angiogenesis
Enhancing immunosupportive mechanisms via anti-angiogenesis Treatment with anti-a
How does checkpoint inhibition perform in the setting of oncogene-driven lung cancer?
How does checkpoint inhibition perform in the setting of oncogene-driven lung cancer
Immunotherapy: from predictive factors to antibiotics
Immunotherapy: from predictive factors to antibiotics Update of CheckMate 9LA Bas
KRAS, MET, ROS1, HER2: current perspectives
KRAS, MET, ROS1, HER2: current perspectives CodeBreaK100: sotorasib Approximately
EGFR-mutant disease: strategies against sensitizing and resistance-mediating mutations
EGFR-mutant disease: strategies against sensitizing and resistance-mediating mutati